StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a research note issued to investors on Sunday. The firm issued a hold rating on the stock.
NovaBay Pharmaceuticals Stock Down 5.6 %
NYSE NBY opened at $0.71 on Friday. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $17.74. The company has a market capitalization of $762,810.00, a P/E ratio of -0.01 and a beta of 0.73. The stock’s 50-day moving average price is $0.74 and its 200-day moving average price is $2.39.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share for the quarter. The firm had revenue of $2.40 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative return on equity of 744.33%. Research analysts anticipate that NovaBay Pharmaceuticals will post -0.17 EPS for the current year.
Institutional Inflows and Outflows
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Read More
- Five stocks we like better than NovaBay Pharmaceuticals
- Best Aerospace Stocks Investing
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Golden Cross Stocks: Pattern, Examples and Charts
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Industrial Products Stocks Investing
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.